华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600521 华海药业

已收盘 12-25 15:00:00

{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":18.3,"timestamp":1735110000000,"preClose":18.7,"halted":0,"volume":10120982,"delay":0,"floatShares":1467000000,"shares":1467000000,"eps":0.7774,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.4,"latestTime":"12-25 15:00:00","open":18.72,"high":18.75,"low":18.2,"amount":186000000,"amplitude":0.0294,"askPrice":18.31,"askSize":1,"bidPrice":18.3,"bidSize":69,"shortable":0,"etf":0,"ttmEps":0.7774,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735176600000},"adr":0,"adjPreClose":18.7,"symbolType":"stock","openAndCloseTimeList":[[1735090200000,1735097400000],[1735102800000,1735110000000]],"highLimit":20.57,"lowLimit":16.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1466755454,"pbRate":3.14,"roa":"--","roe":"12.13%","epsLYR":0.57,"committee":0.399204,"marketValue":26842000000,"floatMarketCap":26842000000,"peRate":23.540005,"changeRate":-0.0214,"turnoverRate":0.0069,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-12-27。"},"requestUrl":"/m/hq/s/600521/tweets","defaultTab":"tweets","newsList":[{"id":"2494697015","title":"华海药业12月25日遭主力抛售1263万元 环比增加321.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494697015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494697015?lang=zh_cn&edition=full","pubTime":"2024-12-25 15:18","pubTimestamp":1735111092,"startTime":"0","endTime":"0","summary":"12月25日, 华海药业股价跌2.14%，报收18.30元，成交金额1.86亿元，换手率0.69%，振幅2.94%，量比1.11。华海药业今日主力资金净流出1263万元，连续3日净流出，上一交易日主力净流出300万元，今日环比增加321.00%。该股近5个交易日下跌1.93%，主力资金累计净流出1797万元；近20日主力资金累计净流入228万元，其中净流入天数为8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225152357a208afe7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225152357a208afe7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","600521","BK0185","BK0188","BK0239","BK0028","BK0012","BK0201"],"gpt_icon":0},{"id":"2492349538","title":"研报掘金丨华福证券：首予华海药业“买入”评级，原料药需求端有望提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2492349538","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492349538?lang=zh_cn&edition=full","pubTime":"2024-12-20 16:06","pubTimestamp":1734681979,"startTime":"0","endTime":"0","summary":"华福证券研报指出，考虑到华海药业(600521.SH)心血管及精神类原料药企业龙头地位及原料药-制剂一体化优势，首次覆盖给予“买入”评级。2023年国内原料药产业受22年疫情相关订单导致的高基数以及下游制剂厂商消化疫情期间的库存影响，包括公司在内的多家原料药企业业绩出现短期波动。当前原料药产量单月同比增长明显，24H1国内原料药产量同比回正，出口量持续增长，或意味着原料药去库存已接近尾声，需求端有望提振。同时考虑到海外专利悬崖下仿制药原料药及制剂出海空间巨大，原料药-制剂一体化企业有望充分受益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220160619984ceff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220160619984ceff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","161027"],"gpt_icon":0},{"id":"2492345744","title":"华福证券：给予华海药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492345744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492345744?lang=zh_cn&edition=full","pubTime":"2024-12-20 08:29","pubTimestamp":1734654559,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对华海药业进行研究并发布了研究报告《原料药制剂一体化龙头，全球化布局加速中》，本报告对华海药业给出买入评级，当前股价为18.65元。采用可比公司估值法，2024-2026年可比公司平均PE分别为20X/16X/13X，考虑到公司心血管及精神类原料药企业龙头地位及原料药-制剂一体化优势，首次覆盖给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为24.95。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122000006738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","161027"],"gpt_icon":0},{"id":"2492970006","title":"【市场】华海药业出手了，抢攻3亿降压药","url":"https://stock-news.laohu8.com/highlight/detail?id=2492970006","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492970006?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:02","pubTimestamp":1734512570,"startTime":"0","endTime":"0","summary":"精彩内容12月18日，CDE官网显示，华海药业的4类仿制药培哚普利氨氯地平片(Ⅲ)上市申请获得承办。培哚普利氨氯地平片(Ⅲ)为复方降压药，2023年在中国三大终端六大市场销售额超过3亿元。华海药业获批上市的高血压用药来源：米内网中国上市药品数据库","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218172613ab8170e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","600521","BK0012","BK0070","BK0188","BK0185","BK0028","BK0239"],"gpt_icon":0},{"id":"2491615686","title":"华海药业阿达木单抗申报上市，礼来替尔泊肽中国第五项适应症申报上市，豪森药业和朱养心药业拿下司来帕格片首仿","url":"https://stock-news.laohu8.com/highlight/detail?id=2491615686","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491615686?lang=zh_cn&edition=full","pubTime":"2024-12-16 21:02","pubTimestamp":1734354167,"startTime":"0","endTime":"0","summary":"华海药业“阿达木单抗”生物类似药申报上市12月14日，中国国家药监局药品审评中心网站最新公示，华海药业阿达木单抗注射液生物类似药上市申请已获得受理。根据CDE官网查询，这是替尔泊肽在中国递交的第五项上市申请，其中两项上市申请此前已经获NMPA批准。在中国，替尔泊肽于今年5月获批首个适应症，用于成人2型糖尿病患者血糖控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216212242a1f32441&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216212242a1f32441&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0201","BK0185","600521","BK0239","BK0070","BK0028","BK0012"],"gpt_icon":0},{"id":"2491550516","title":"华海药业12月16日遭主力抛售3739万元 环比增加643.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491550516","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491550516?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:18","pubTimestamp":1734333496,"startTime":"0","endTime":"0","summary":"12月16日, 华海药业股价跌2.67%，报收19.34元，成交金额3.43亿元，换手率1.20%，振幅3.02%，量比0.69。华海药业今日主力资金净流出3739万元，连续3日净流出，上一交易日主力净流出503万元，今日环比增加643.34%。净流出前三个股分别为华东医药、复星医药、华海药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152248a1f25841&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152248a1f25841&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","600521","BK0012","BK0201","BK0188","BK0185","BK0028","BK0239"],"gpt_icon":0},{"id":"2491638764","title":"华海药业：甲磺酸雷沙吉兰片、西格列汀二甲双胍片(II)拟中选本次集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491638764","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491638764?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:28","pubTimestamp":1734312492,"startTime":"0","endTime":"0","summary":"近日，华海药业发布关于公司产品拟中选第十批全国药品集中采购的公告。披露公司产品甲磺酸雷沙吉兰片、西格列汀二甲双胍片拟中选本次集中采购。西格列汀二甲双胍片 配合饮食和运动治疗，用于经二甲双胍单药治疗血糖仍控制不佳或正在接受二者联合治疗的2型糖尿病患者，拟中选424.35万片，拟中选价格0.2968元/片。2022 年11月，公司收到国家药品监督管理局核准签发的西格列汀二甲双胍片《药品注册证书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093007a1f1a602&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093007a1f1a602&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0188","600521","BK0012","BK0201","BK0185","BK0070","BK0028"],"gpt_icon":0},{"id":"2491734527","title":"华海药业最新公告：两产品拟中选第十批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491734527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491734527?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:35","pubTimestamp":1734078913,"startTime":"0","endTime":"0","summary":"华海药业公告称，12月12日，公司参加了国家组织药品联合采购办公室组织的第十批全国药品集中采购的投标工作，公司产品甲磺酸雷沙吉兰片、西格列汀二甲双胍片(II)拟中选本次集中采购。目前，公司已与联采办签订了《全国药品集中采购拟中选品种主/备供地区备忘录》，上述产品的采购协议签订等后续事项及对公司未来业绩影响尚存在不确定性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300028299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600521","BK0012","BK0201","BK0188","BK0185","BK0028","BK0239"],"gpt_icon":0},{"id":"2491431033","title":"华海药业最新公告：子公司药品上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491431033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491431033?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:18","pubTimestamp":1734077891,"startTime":"0","endTime":"0","summary":"华海药业公告，公司全资子公司华海生物收到国家药监局核准签发的阿达木单抗注射液（HOT-3010闲康乐®）境内生产药品注册上市许可申请的《受理通知书》。该药物主要用于治疗类风湿关节炎、强直性脊柱炎、银屑病等。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300027814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0239","BK0188","BK0201","600521","BK0185","BK0012"],"gpt_icon":0},{"id":"2491326326","title":"华海药业两种药品中选药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491326326","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491326326?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:08","pubTimestamp":1734077300,"startTime":"0","endTime":"0","summary":"财中社12月13日电华海药业 发布关于公司产品拟中选第十批全国药品集中采购的公告。公司参加了由国家组织药品联合采购办公室进行的投标，甲磺酸雷沙吉兰片和西格列汀二甲双胍片拟中选。采购周期自中选结果执行之日起至2027年12月31日。2024年前三季度，华海药业实现收入72.48亿元，归母净利润10.31亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161917a1eb6b09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161917a1eb6b09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","600521","BK0012","BK0201","BK0188","BK0185","BK0028","BK0239"],"gpt_icon":0},{"id":"2491326300","title":"华海药业子公司阿达木单抗注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491326300","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491326300?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:08","pubTimestamp":1734077280,"startTime":"0","endTime":"0","summary":"财中社12月13日电华海药业 发布关于子公司药品上市许可申请获得受理的提示性公告。公司下属全资子公司浙江华海生物科技有限公司近日收到国家药监局核准签发的阿达木单抗注射液境内生产药品注册上市许可申请的《受理通知书》。截至目前，公司在该项目上已合计投入研发费用约1.93亿元。2024年前三季度，华海药业实现收入72.48亿元，归母净利润10.31亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161104ab74bd4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161104ab74bd4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","BK0070","BK0201","BK0239","BK0028","BK0185","BK0188","BK0012"],"gpt_icon":0},{"id":"2491310596","title":"华海药业(600521.SH)：部分产品拟中选第十批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491310596","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491310596?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:47","pubTimestamp":1734076078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，公司参加了国家组织药品联合采购办公室组织的第十批全国药品集中采购的投标工作，公司产品甲磺酸雷沙吉兰片、西格列汀二甲双胍片(II)拟中选本次集中采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0185","BK0070","BK0188","600521","BK0012","BK0201","BK0239"],"gpt_icon":0},{"id":"2491831056","title":"华海药业(600521.SH)：阿达木单抗注射液上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491831056","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491831056?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:46","pubTimestamp":1734075963,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，公司下属全资子公司浙江华海生物科技有限公司(简称“华海生物”)收到国家药品监督管理局核准签发的阿达木单抗注射液(简称“HOT-3010闲康乐®”)境内生产药品注册上市许可申请的《受理通知书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华海药业(600521.SH)：阿达木单抗注射液上市许可申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0012","BK0201","BK0239","BK0028","BK0185","600521","BK0070"],"gpt_icon":0},{"id":"2490307098","title":"华海药业最新公告：获得二甲双胍恩格列净片（I）药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490307098","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490307098?lang=zh_cn&edition=full","pubTime":"2024-12-10 18:11","pubTimestamp":1733825501,"startTime":"0","endTime":"0","summary":"华海药业公告，公司于近日收到国家药监局核准签发的二甲双胍恩格列净片（I）的《药品注册证书》。该药品用于配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121000035542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0185","BK0070","BK0239","BK0012","BK0028","BK0201","BK0188"],"gpt_icon":0},{"id":"2488165832","title":"华海药业：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2488165832","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488165832?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:17","pubTimestamp":1733307464,"startTime":"0","endTime":"0","summary":"每经AI快讯，华海药业 12月4日晚间发布公告称，浙江华海药业股份有限公司于近日收到国家药品监督管理局核准签发的达格列净片的《药品注册证书》。2023年1至12月份，华海药业的营业收入构成为：成品药销售占比59.35%，原材料及中间体销售占比38.03%，技术服务占比1.47%，其他行业占比0.36%，进出口贸易占比0.06%。华海药业的董事长是李宏，男，63岁，学历背景为本科；总经理是陈保华，男，62岁，学历背景为本科。截至发稿，华海药业市值为265亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204181814abf5464d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204181814abf5464d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0185","BK0012","BK0070","BK0239","BK0201","600521","BK0188"],"gpt_icon":0},{"id":"2488591168","title":"华海药业最新公告：公司获得达格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488591168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488591168?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:01","pubTimestamp":1733306518,"startTime":"0","endTime":"0","summary":"华海药业公告，公司近日收到国家药监局核准签发的达格列净片的《药品注册证书》。该药品用于治疗2型糖尿病，申请事项为药品注册（境内生产），注册分类为化学药品4类。达格列净片最早由百时美施贵宝和阿斯利康共同研发，于2012年11月在欧洲上市，国内于2017年3月批准上市。目前国内市场销售金额约人民币33.38亿元。公司在达格列净片研发项目上已投入研发费用约人民币744万元。本次获得药品注册证书将丰富公司产品线，提升市场竞争力，对经营发展具有积极作用。但产品生产和销售受国家政策、市场环境等因素影响，投资者需谨慎决策，注意防范投资风险。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400032769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0185","BK0188","BK0028","BK0239","600521","BK0070","BK0201"],"gpt_icon":0},{"id":"2488515074","title":"华海药业(600521.SH)：达格列净片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488515074","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488515074?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:56","pubTimestamp":1733306171,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华海药业(600521.SH)：达格列净片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0185","BK0070","BK0188","600521","BK0012","BK0201","BK0239"],"gpt_icon":0},{"id":"2488628605","title":"华海药业12月02日主力资金流入1059万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2488628605","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488628605?lang=zh_cn&edition=full","pubTime":"2024-12-02 15:18","pubTimestamp":1733123905,"startTime":"0","endTime":"0","summary":"12月02日, 华海药业股价涨1.70%，报收18.51元，成交金额3.42亿元，换手率1.25%，振幅3.30%，量比1.52。华海药业今日主力资金净流入1059万元，连续3日净流入，上一交易日主力净流入4558万元，今日环比减少76.77%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为50.00%，平均涨幅为1.44%。该股近5个交易日上涨7.37%，主力资金累计净流入6205万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出6170万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202152428a2659843&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202152428a2659843&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0185","BK0070","BK0188","600521","BK0012","BK0201","BK0239"],"gpt_icon":0},{"id":"2487658967","title":"华海药业11月29日获主力加仓4558万元 环比增加1384.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487658967","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487658967?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:20","pubTimestamp":1732864803,"startTime":"0","endTime":"0","summary":"11月29日, 华海药业股价涨4.60%，报收18.20元，成交金额3.68亿元，换手率1.39%，振幅5.75%，量比1.76。华海药业今日主力资金净流入4558万元，上一交易日主力净流入307万元，今日环比增加1384.69%。该行业中净流入前三个股分别为华东医药、华海药业、科伦药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129153345abe7f98a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129153345abe7f98a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0185","BK0239","BK0028","BK0188","BK0070","BK0201","600521","BK0012"],"gpt_icon":0},{"id":"2487930239","title":"华海药业涨5% 生物医药产业迎利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2487930239","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487930239?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:08","pubTimestamp":1732856891,"startTime":"0","endTime":"0","summary":"机构分析山西证券认为，华海药业仿制药集采影响缓和，麻醉等创新药快速放量，2024年H1麻醉产品收入5.2亿元，占比已达30.7%，驱动整体业绩增长。主营业务及业绩华海药业公司主营业务为多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。最新财报显示，今年三季报，华海药业实现营业收入72.48亿元，同比增长16.76%，净利润为10.31亿元，同比增长42.92%，基本每股收益为0.71元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130944a25e3d87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130944a25e3d87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0185","BK0188","600521","BK0239","161726","BK0012","399441","BK0028","BK0201"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.068},{"period":"3month","weight":0.1258},{"period":"6month","weight":0.1016},{"period":"1year","weight":0.3236},{"period":"ytd","weight":0.2894}],"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","perCapita":"26336股","boardName":"医药制造业","registeredCapital":"146675万元","compareEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":0.0387},{"period":"3month","weight":0.1717},{"period":"6month","weight":0.152},{"period":"1year","weight":0.1626},{"period":"ytd","weight":0.1407}],"survey":"　　浙江华海药业股份有限公司主营业务为多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品有心血管类、精神障碍类、神经系统类、抗感染类等为主导的产品系列。2023年4月，公司荣获“全国五一劳动奖状”和“浙江省五一劳动奖状”，同月，公司被浙江省药品检查中心认定为浙江省职业检查“尖兵领航”工程实训基地；2023年6月，公司入选米内网颁发的2022年度中国化药企业百强等。","serverTime":1735113469090,"listedPrice":15.55,"stockholders":"55692人(较上一季度减少5.68%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}